public-content

Is Peptide Therapy Legal? A Plain-English Regulatory Guide

Peptide therapy exists in a complicated regulatory space. Here's what the law actually says about compounded peptides, prescriptions, FDA oversight, and telehealth — without the spin.

Traves Brady

13 Apr 2026 — 8 min read

PC-02 — Is Peptide Therapy Legal? A Plain-English Guide to the Regulatory Framework

The Short Answer

Yes — peptide therapy can be legal. No — it is not a free zone. The legality of any specific peptide therapy depends on which peptide is being used, whether it has an FDA-approved indication, whether a valid prescription exists, which regulatory lane the business operates in, and what claims are being made about it.

This post maps that terrain clearly. It is not legal advice. For your specific situation, consult a healthcare attorney or pharmacy regulatory counsel.

How Peptide Therapy Intersects With Three Different Regulatory Systems

Most people think about peptide regulation as a single question — is this legal? — but the actual regulatory landscape involves at least three separate systems, each with its own rules, enforcement mechanisms, and penalties.

1. FDA — federal drug regulatory framework

The FDA regulates peptides under the FD&C Act. Depending on the peptide and how it is marketed, it may be regulated as an approved drug, an unapproved new drug, or a compounded product.

2. FTC — federal consumer protection framework

The FTC regulates how peptide products and services are marketed — including claims made by clinics, telehealth platforms, and influencers. If you say your peptide treats a condition, the FTC has jurisdiction over that claim.

3. State pharmacy boards and medical boards — state regulatory framework

State boards are often the first line of enforcement for peptide prescribing and dispensing. They license the pharmacies and providers involved, investigate complaints, and can take disciplinary action that ends a practice.

Understanding which system applies to which part of your situation — and where they overlap — is the foundation of understanding whether a specific peptide business is operating legally.

FDA Jurisdiction: Compounded Peptides and the "Essentially a Copy" Problem

The FDA's position on compounded peptides is the core of the legal question in most peptide business contexts.

The compounding framework

Under Section 503A of the FD&C Act, licensed pharmacists and physicians can compound drugs — including peptides — for individual patients based on a valid prescription. The key requirements are:

The prescription must be for a specific patient
There must be a documented medical need that an FDA-approved drug cannot meet
The compounding must be done by a licensed pharmacy
The pharmacy must comply with USP standards for compounding

Under Section 503B, outsourcing facilities can compound drugs for office use — meaning they can produce batches for clinics and practitioners without a specific patient prescription in advance. 503B facilities must register with the FDA, comply with cGMP standards, and meet certain labeling requirements.

The "essentially a copy" problem

In 2020 and 2023, the FDA issued guidance that identified a list of compounded peptides that are "essentially copies" of FDA-approved drugs. If a compounded peptide is essentially a copy of an approved drug, it falls outside the scope of permissible compounding under Section 503A.

BPC-157 has been a focal point of this enforcement attention. It is not an FDA-approved drug. There is no FDA-approved version of BPC-157. But the FDA's position is that if a peptide is being promoted for an indication that an approved drug addresses — and that approved drug could be used by the patient — then compounding that peptide may be considered an "essentially a copy" violation.

What this means practically:

Peptides with no FDA-approved equivalent are in a different category than peptides that are copies of approved drugs
The regulatory status of specific peptides changes as FDA guidance evolves
Operators who are not tracking FDA compounding guidance are operating with blind spots

The current FDA guidance document on compounding — including the essentially a copy list — is publicly available. Any legitimate peptide operator should be familiar with it.

FTC Jurisdiction: When Health Claims Become Enforcement Triggers

The FTC has jurisdiction over how peptide products and services are marketed to consumers. This includes claims made on websites, in social media content, in advertising, and by influencers and affiliates.

The basic rule

Under Section 5 of the FTC Act, claims made in connection with the sale of goods or services must be truthful, not misleading, and substantiated by competent and reliable scientific evidence before they are made.

For health-related claims — including peptide efficacy claims — the FTC requires a higher level of substantiation than most businesses realize. Specifically:

Health claims for dietary supplements and conventional foods require "competent and reliable scientific evidence" — typically randomized controlled trials or equivalent evidence
Health claims for drug products require the FDA's evidentiary standard for approved drugs
Testimonial claims must reflect typical results, and must not make claims that are not substantiated for the general population

The disease claim line

The line the FTC draws most aggressively is the line between wellness and disease claims:

Wellness/structure/function claims: "Supports healthy sleep patterns" — permitted with appropriate substantiation
Disease claims: "Treats insomnia" or "reduces anxiety" — requires FDA approval or equivalent evidence

The FTC has been explicit that the disease claim line is not determined by the words used — it is determined by the impression the claim creates on a reasonable consumer. "Supports your body's natural healing response" for a wound healing peptide can be a disease claim if the consumer impression is that it treats a disease or condition.

What this means for peptide businesses:

Every claim on your website, in your advertising, and in your influencer content is an FTC jurisdiction question
The FTC does not just go after large companies — it actively pursues small wellness businesses
The FTC's 2023 enforcement in the supplement and peptide space specifically targeted businesses making unsubstantiated health claims through influencer and affiliate marketing

State Pharmacy Boards: Where Most Enforcement Actually Happens

Federal enforcement gets the attention. State enforcement is where most peptide business enforcement actually plays out.

State pharmacy boards

State boards license compounding pharmacies and investigate complaints about unprofessional conduct, unsafe compounding practices, and violations of state pharmacy law. In the peptide context, common state board enforcement triggers include:

Dispensing peptides without a valid prescription
Using non-FDA-registered pharmacies
Failing to maintain adequate quality and testing standards
Dispensing compounds that are essentially copies of approved drugs under state law
Inadequate patient counseling and consent documentation

State medical boards

Medical boards license the prescribers — physicians, nurse practitioners, physician assistants — who write peptide prescriptions. State boards have been increasingly focused on peptide prescribing practices, particularly:

Prescribing without adequate clinical evaluation
Using standardized protocols without individualized assessment
Failure to maintain adequate medical records
Prescribing for indications not supported by the clinical evidence

State telemedicine regulations

Most states have specific telemedicine regulations that govern how care can be provided remotely. These vary significantly by state. Some states require an existing patient-provider relationship before prescribing. Some require specific informed consent for telemedicine. Some prohibit prescribing certain categories of medications via telemedicine without additional documentation.

A peptide business operating across multiple states must track state-specific telemedicine requirements for every state in which it serves patients.

The Telehealth Dimension

Telehealth has been one of the most significant growth drivers for the peptide industry — and one of the most significant compliance complexity adders.

The federal telehealth framework

At the federal level, the DEA has historically required an in-person medical evaluation before prescribing controlled substances via telemedicine, with an exception for telemedicine encounters established before the COVID-19 public health emergency. That exception has been extended repeatedly and its current status should be tracked closely.

For non-controlled substance peptides — which is most of the peptide prescribing in the wellness space — federal telehealth restrictions are less stringent, but state-level rules apply.

State telehealth variation

State telemedicine regulations are highly variable. Some states:
- Require an in-person evaluation before prescribing via telemedicine
- Allow prescribing based on a telemedicine encounter with no additional requirements
- Require specific informed consent documentation for telemedicine
- Require the prescribing provider to be licensed in the state where the patient is located — not just licensed in their own state

The legitimate telehealth model

The legitimate use of telehealth for peptide prescribing requires:

A real clinical encounter — not a questionnaire
An independent clinical determination by a licensed provider
Documentation of medical necessity
Appropriate follow-up and monitoring
Prescribing that is consistent with the standard of care

A "protocol" that routes every patient through the same peptide regimen based on a questionnaire, with no individualized clinical assessment, is not a telehealth encounter — it is a prescribing mill with a digital interface.

Common Legal Gray Areas

These are the areas where operators most frequently operate without realizing they are in a legal gray zone:

"Our pharmacy is licensed, so it's legal."

Licensure is necessary but not sufficient. A licensed pharmacy can still compound illegally — by making "essentially copies" of approved drugs, by failing to meet USP compounding standards, or by dispensing without a valid prescription.

"The patient was seen by a provider, so the prescription is valid."

A prescription based on a 5-minute questionnaire with no meaningful clinical encounter, issued by a provider who never actually speaks to the patient, is not a valid prescription under most state medical board standards. The prescription may be issued — but the clinical encounter may not satisfy the standard of care.

"We're not claiming to treat a disease, we're supporting wellness."

The FTC's standard is consumer impression, not the exact words used. "Supports your body's natural testosterone production" for a testosterone peptide may still constitute an implied disease claim (testosterone deficiency) depending on the context and the consumer impression it creates.

"We're not selling a drug, we're providing a service."

The structure of your business does not determine whether your product is a drug. If what you are providing is a peptide for a therapeutic purpose, it is subject to drug regulations regardless of how you have structured the transaction or named the service.

What Legitimate Peptide Therapy Actually Looks Like

Legitimate peptide therapy is not complicated to describe — but it requires more clinical infrastructure than many of the businesses operating in this space are willing to build.

A legitimate peptide prescribing relationship involves:

An in-person or real-time telehealth clinical evaluation by a licensed provider
A documented medical history and clinical assessment
An individualized determination that peptide therapy is clinically appropriate
Informed consent that accurately describes the peptide, its status (FDA-approved or compounded), and the risks
A prescription for a specific peptide for a specific patient
A dispensing pharmacy that is appropriately licensed and registered
Ongoing clinical monitoring and follow-up
Documentation that reflects all of the above

What it does not involve:

A questionnaire that routes every patient to the same protocol
A provider who never speaks with the patient
A pharmacy that uses "distribution" language in its agreements
Marketing that makes disease claims or unsubstantiated efficacy claims
An agreement that authorizes the "distributor" to hold inventory and fulfill prescriptions independently

Questions to Ask Your Provider

If you are a patient considering peptide therapy, these are the questions that will tell you whether your provider is operating legitimately:

Is the peptide I am receiving an FDA-approved drug or a compounded peptide?
Is this peptide on the FDA's "essentially a copy" list?
Who is the dispensing pharmacy, and can I verify their license and registration?
What is the clinical rationale for this specific peptide for my specific case?
What is your prescribing relationship with the pharmacy — do you have a financial interest in which pharmacy I use?
How do you monitor my response to this therapy and adjust the protocol?
What adverse events or side effects should I report, and how do I report them?

A legitimate provider will answer all of these questions directly. A provider who cannot or will not answer them is a provider you should be cautious about.

Ready to go deeper?

The regulatory framework for peptide businesses is complex — but it is navigable with the right guidance. AEG Compliance Members have access to the full legal framework, draft agreement templates for pharmacy and supplier relationships, and ongoing compliance intelligence for peptide operators.

→ [Join as a Member — $27/month(https://aim-elemental-group-peptide-compliance-awareness.ghost.io/membership/)
→ [See what's in the library →(https://aim-elemental-group-peptide-compliance-awareness.ghost.io/resources/)
→ [Read: The Four Legal Lanes Peptide Businesses Actually Operate In →(https://aim-elemental-group-peptide-compliance-awareness.ghost.io/four-legal-lanespeptide-businesses-2/)

This post is for educational purposes only and does not constitute legal or medical advice. The regulatory landscape for peptide therapy is complex and fact-specific. Consult qualified healthcare regulatory counsel for guidance on your specific situation.

Ready to go deeper?

Join as a Member — $27/month →